IngredientsDiosgenin, a phytosteroid spirostanol sapogenin, is the product of hydrolysis — by acids, strong bases, or enzymes — of saponins extracted from the tubers of Dioscorea wild yam species. Its full systematic name is (22R,25R)-spirost-5-en-3β-ol, and it carries the CAS number 512-04-9. Its molecular formula is C₂₇H₄₂O₃, with a molecular weight of 414.627 g/mol.
Spirostan-type saponins are the most common steroid saponins in plants. They possess a hexacyclic aglycone, such as diosgenin or tigogenin, in which the 3-OH group is usually decorated with an oligosaccharide chain. As an aglycone (i.e., the non-sugar portion of a saponin glycoside), diosgenin is liberated from its glycosidic parent compounds — most notably dioscin and protodioscin — upon hydrolysis. The presence of a hydroxyl group at the 3-beta position and a double bond between carbons 5 and 6 makes it highly reactive and structurally analogous to endogenous human steroid precursors like cholesterol and DHEA.
The compound has been known since at least 1936, when Takeo Tsukamoto and Yoshio Ueno at the Pharmaceutical Institute of Kanazawa Medical School (Japan; now part of Kanazawa University) produced it via acid hydrolysis of the glycoside dioscin, obtained from the species D. tokoro. In subsequent articles, Tsukamoto and Ueno described the structure and properties of diosgenin. Its application in the synthesis of cortisone and other drugs was later reported by Marker and coworkers.
The Dioscorea genus is the main source of diosgenin, and approximately 137 species of this genus contain the compound, including Dioscorea nipponica, Dioscorea zingiberensis, Dioscorea composita, and Dioscorea deltoidea. It is also present in extractable amounts from many other Dioscorea species, including D. althaeoides, D. colletti, D. floribunda, D. futschauensis, D. hispida, D. hypoglauca, D. mexicana, D. nipponica, D. panthaica, D. parviflora, D. septemloba, and D. zingiberensis.
Diosgenin is also isolated from other botanicals including Trigonella foenum-graecum (fenugreek), Costus speciosus, Tribulus terrestris L., Rhizoma polygonati, and Paris polyphylla. Primary sources include Smilax china, Rhizoma polygonati, Solanum incanum, Solanum xanthocarpum, Dioscorea villosa, Trigonella foenum-graecum (fenugreek), and Dioscorea Linn (wild yams).
The diosgenin distribution within plants is found in rhizomes, tubers, roots, and seeds. It is commercially obtained from wild yam tubers and rootstock.
Diosgenin is mostly produced from the hydrolysis of steroidal saponins in the presence of strong acid, base, or enzyme catalyst, while microbial transformation techniques are gaining attention due to their highly specific nature and low cost. From a suitable source, the sapogenins are isolated by acid hydrolysis of the saponin; previous fermentation of the material for some 4–10 days often gives a better yield. The water-insoluble sapogenin is then extracted with a suitable organic solvent.
As a commercial and consumer ingredient, diosgenin and its parent plant material appear in multiple forms: dried Dioscorea root and rhizome powders, standardized dry extracts (typically standardized to a percentage of diosgenin content), topical creams containing wild yam extract, and soft-gel capsules formulated in oil carriers. Preliminary animal experiments indicated that an oil solvent mediated the most efficient distribution of diosgenin into the blood and brain after oral administration; test samples for human trials were therefore prepared with olive oil and formulated as soft capsules.
In the 18th and 19th centuries, herbalists used wild yam (Dioscorea villosa) to treat menstrual cramps and problems related to childbirth, as well as for upset stomach and coughs. Wild yam was popularized by the Eclectic medical movement in the 19th century for its supposed antispasmodic properties and was therefore prescribed for biliary colic and spasm of the bowel. It was also promoted for the relief of nausea in pregnancy and for amenorrhea and dysmenorrhea. Wild yam has been used for urinary tract infections, rheumatoid arthritis, cholera, nervous excitement, and flatulence.
Diosgenin is a constituent of Dioscorea nipponica and is widely used as a traditional medicinal plant in Korea to treat diabetes, inflammation, and neurodegenerative diseases. Species of Dioscorea have also featured in traditional Chinese medicine as sources of steroidal saponins; dioscin, one of the most widely distributed steroid saponins in plants and the glycoside precursor of diosgenin, exhibits antitumor, antiviral, antifungal, anti-inflammatory, and immunostimulatory activities and has been found in a number of traditional Chinese herbal medicines.
During periods of food scarcity, Dioscorea species have served as a source of conventional foods and as traditional medicine. The accessibility of bioactive compounds from yams such as flavonoids, tannins, and steroidal saponins like diosgenin and dioscorin has attracted many researchers to investigate the matrix. In addition to providing energy, yam has a variety of appealing dietary elements and therapeutic benefits, including antioxidative, hypocholesterolaemic, antibacterial, hypoglycaemic, and immunomodulatory activities.
Diosgenin's single most historically consequential role has been as a pharmaceutical raw material. Diosgenin is a steroid sapogenin available from natural sources, used for the commercial synthesis of steroid products like cortisone, pregnenolone, and progesterone. Its most significant application has been as a precursor in an economical semi-synthesis of progesterone, developed by Marker before World War II — a route known as the Marker degradation, which has been designated as an International Historic Chemical Landmark by the American Chemical Society and the Sociedad QuÃmica de México.
The prehistory of the Pill's chemistry started with Russell E. Marker, an American organic chemist, who realized in the early 1940s that the "Mexican route," an effective method of side-chain degradation, could convert diosgenin from Dioscorea mexicana into progesterone. Together with Emeric Somlo and Federico Lehmann, he co-founded Syntex and began the manufacture of progesterone. Although Marker eventually stepped back from active chemistry, his plant-steroid platform enabled Syntex to develop cortisone and sex-steroid syntheses at scale, which were essential for later contraceptive research.
Diosgenin is mainly used to synthesize other steroidal compounds, such as the sex hormones progesterone and testosterone, and the corticosteroids cortisone and cortisol. Until 1970, diosgenin isolated from the Mexican yam was the sole source for steroidal contraceptive manufacture.
A critical pharmacological point: conversion of diosgenin to estrogen, progesterone, or any other steroid does not occur in the human body. Neither can it be converted to progesterone in the body; this process can only occur in the laboratory. This distinction is important when evaluating claims about wild yam products sold for hormonal support.
Diosgenin itself is the aglycone (non-glycosidic) form. In planta, it exists bound to sugar moieties as saponin glycosides. The most common parent glycosides include:
Progesterone, pregnenolone, cortisone, and other steroids can be synthesized from diosgenin, which comprises more than 60% of commercial synthetic steroids. The compound's steroidal backbone — the tetracyclic ring system characteristic of all steroids — is what confers both its pharmaceutical utility and its broad range of biological activities.
Diosgenin exhibits potent anti-inflammatory properties by inhibiting the NF-κB signaling pathway and reducing the expression of pro-inflammatory cytokines such as TNF-α and IL-6. More detailed mechanistic work has elaborated on downstream targets: diosgenin inhibits production of reactive oxygen species (ROS), interleukin-1 (IL-1), and IL-6. Inhibition of these inflammatory mediators appears to be at the transcriptional level, as diosgenin decreased LPS/IFN-γ-induced NF-κB and AP-1 activity. Diosgenin blocked CK2 activation and phosphorylation of c-Jun NH₂-terminal kinase (JNK), but not that of p38 MAPK and ERK 1/2.
Diosgenin upregulates pro-apoptotic Bax expression and downregulates anti-apoptotic Bcl-2 expression, leading to mitochondrial dysfunction and caspase activation. It also inhibits Cyclin D1 expression, arresting the cell cycle at the G1/S phase and suppressing cell proliferation.
Diosgenin exerts significant antitumor potential via induction of apoptosis and suppression of inflammation. It also inhibited the invasion, metastasis, angiogenesis, and proliferation of various cancer cell lines. Accordingly, targeting inflammation-related pathways, including NF-κB and STAT3, is one of the main anticarcinogenic mechanisms of diosgenin.
It exhibits anticancer, cardiovascular-protective, antidiabetic, neuroprotective, immunomodulatory, estrogenic, and skin-protective effects, mainly by inducing apoptosis, suppressing malignant transformation, decreasing oxidative stress, preventing inflammatory events, promoting cellular differentiation and proliferation, and regulating T-cell immune response. It interferes with cell death pathways and their regulators to induce apoptosis. Diosgenin antagonizes tumor metastasis by modulating epithelial–mesenchymal transition and actin cytoskeleton to change cellular motility, suppressing degradation of the matrix barrier, and inhibiting angiogenesis.
Numerous studies have shown that diosgenin has potential therapeutic value for lipid metabolism diseases via various pathways and mechanisms, such as controlling lipid synthesis, absorption, and inhibition of oxidative stress. Numerous studies and clinical trials suggested that diosgenin can reduce hyperlipidemia by lowering the amount of low-density lipoproteins, interfering with the absorption of cholesterol, and increasing its excretion. One proposed molecular target is NPC1L1 (Niemann-Pick C1-Like 1), a cholesterol importer protein that regulates intestinal absorption of cholesterol and fat-soluble vitamins.
Diosgenin was found to stimulate neurite regeneration and synapse formation in Alzheimer's disease model mice, and diosgenin-rich yam extract enhanced cognitive function in healthy people and in normal mice. Animal studies have identified involvement of the 1,25D3-MARRS signaling pathway: research focused on the 1,25D3-MARRS pathway as a critical target for anti-Alzheimer's therapy and demonstrated that diosgenin activated this signaling pathway.
Recent studies indicated that diosgenin may protect against bone loss, namely in experimental models of senescence, menopause, and retinoic acid-induced osteoporosis. However, the mechanism of action is still not fully clear but may be associated with modulation of the receptor activator of NF-κB ligand/osteoprotegerin (RANKL/OPG) ratio.
In in vitro and in vivo models it was demonstrated that diosgenin exerts antithrombotic activity via inhibition of platelet aggregation and thrombosis and by prolonging APTT, PT, and TT in rats in a dose-dependent manner.
Biochemical and cell-based studies indicated that diosgenin functions as a selective RORγ inverse agonist by inducing both coactivator and corepressor binding to RORγ, thereby uncovering a molecular mechanism for the actions of this natural compound. RORγ is a nuclear receptor involved in metabolic and autoimmune diseases, making this a potentially important mechanism for understanding diosgenin's anti-inflammatory and metabolic effects.
Human/Clinical Evidence (Limited but Positive): A placebo-controlled, randomized, double-blind, crossover study recruited 28 healthy volunteers (age: 20–81 years) from Toyama Prefecture, Japan. Preliminary animal experiments indicated that oil solvent mediated the most efficient distribution of diosgenin into the blood and brain after oral administration; test samples were therefore prepared with olive oil and formulated as soft capsules. The intake period was 12 weeks, and a 6-week washout period separated the two crossover intake periods. The Japanese version of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) test was used for neurocognitive assessment, with adverse effects monitored through blood testing.
Diosgenin-rich yam extract consumption for 12 weeks yielded significant increases in total RBANS score. Among the 12 individual standard cognitive subtests, diosgenin-rich yam extract use significantly improved semantic fluency. No adverse effects were reported. The diosgenin-rich yam extract treatment appeared to safely enhance cognitive function in healthy adults. This study demonstrated for the first time that yam extract rich in diosgenin can safely and effectively enhance cognitive function in healthy adults (RBANS total score +4.25 points, p = 0.0129), with more pronounced effects in individuals aged 47 years and older, offering a new strategy for Alzheimer's disease prevention or early intervention.
A subsequent clinical investigation extended these findings to a clinical population: in a study investigating the efficacy and safety of yam extract in patients with mild cognitive impairment (MCI) and mild Alzheimer's disease, patients were administered either diosgenin-rich yam extract or placebo for 24 weeks.
Preclinical Evidence: Animal model studies showed that the compound diosgenin remarkably promoted axonal regrowth under the pathological conditions of Alzheimer's disease. In a transgenic 5XFAD mouse model of AD, treatment with diosgenin recovered memory function, reduced axonal and synaptic degeneration, and decreased the level of Aβ plaques in the brain.
Evidence Strength: Preliminary. One small crossover RCT (n=28 healthy adults) with a statistically significant cognitive outcome is promising but insufficient to draw clinical conclusions. The evidence is strengthened by convergent preclinical data but requires replication in larger and more diverse human populations.
Preclinical Evidence: Animal and clinical studies have been summarized regarding diosgenin's toxicity, pharmacological mechanism, and research advances related to lipid metabolism, especially in obesity, hyperlipidemia, nonalcoholic fatty liver disease, atherosclerosis, and diabetes. Animal studies have consistently shown that diosgenin can lower LDL cholesterol and triglycerides and raise HDL cholesterol, with the proposed mechanism being interference with intestinal cholesterol absorption via NPC1L1.
Human Evidence: The existing human data on lipid effects come largely from indirect sources. In the menopausal wild yam cream crossover study, no changes were recorded in weight, systolic or diastolic blood pressure, total serum cholesterol, triglyceride, or high-density lipoprotein cholesterol. This finding suggests that topical wild yam extracts, at the doses used in that study, do not meaningfully alter lipid profiles in healthy menopausal women, though it does not rule out effects in dyslipidemic populations or with oral standardized preparations.
Evidence Strength: Predominantly preclinical (animal and in vitro). Human clinical evidence specific to diosgenin's lipid-lowering effects is lacking. Existing data do not confirm a clinically meaningful lipid effect in humans.
Human Evidence: A placebo-controlled, randomized, double-blind, cross-over study was conducted on 23 healthy women suffering from symptoms of menopause. All candidates were treated with wild yam cream or placebo for up to three months, and no significant adverse effects were observed in both treatments. Additionally, no changes were recorded in weight, systolic or diastolic blood pressure, total serum cholesterol, triglyceride, high-density lipoprotein cholesterol, glucose, or estradiol.
Currently, its use as a natural hormone supplement appears to be based on the unsupported concept that it is a natural source or precursor of progesterone. This concept is chemically inaccurate: diosgenin has been shown to have some oestrogenic activity, but lacks progesterogenic activity. Neither can it be converted to progesterone in the body; this process can only occur in the laboratory.
Evidence Strength: Weak. The available randomized clinical trial found no significant benefit on menopausal symptoms or biomarkers with topical wild yam cream. Clinical trials specific to oral diosgenin for menopause are lacking.
In Vitro and Animal Evidence: Diosgenin displayed antiproliferative effects in HEp-2 and M4Beu cell lines via enhancing the production and release of apoptosis-inducing factors, increasing the Bax/Bcl-2 ratio, modulating caspase-3, and facilitating the activation of p53. Diosgenin therapy inhibited cell growth, apoptosis, and cell cycle arrest by suppressing NEDD4 expression in human PC-3 prostate cancer cells. In lung cancer models, diosgenin facilitated cisplatin-induced apoptosis via oxidative DNA damage in A549 non-small cell lung carcinoma cells.
A study published in 2009 on breast cancer cells showed that diosgenin modulates AKT to regulate breast cancer cell survival and that this drug has no effect on normal breast epithelial cells (MCF-10A), demonstrating selective toxicity to cancer cells.
In colon cancer models, diosgenin has been shown to inhibit aberrant crypt foci formation and to suppress 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase expression, linking its anticancer activity to cholesterol synthesis pathway disruption in cancer cells.
Evidence Strength: Exclusively preclinical (cell culture and animal studies). No published clinical trials in human cancer patients have been identified. The mechanistic preclinical data are extensive and convergent across multiple cancer types (colon, breast, prostate, lung, gastric), but the leap to clinical application has not been made.
The natural antioxidant compound diosgenin possesses antidiabetic biological activities and helps in the management of these diseases. In animal models of diabetic peripheral neuropathy, male C57 mice fed a high-fat diet for 8 weeks and injected with streptozotocin (100 mg/kg for 2 consecutive days) were divided into groups receiving low-dose diosgenin (50 mg/kg) or high-dose diosgenin (100 mg/kg). Treatment started 6 weeks after the induction of diabetes and continued for 8 weeks. Diosgenin treatment was associated with neuroprotective effects mediated via the Nrf2/HO-1 antioxidant pathway.
Diosgenin exhibited a protective effect on the kidney in diabetic rats, implying that it could be a potential candidate for treatment of diabetes with renal-associated complications.
Evidence Strength: Preclinical only. Mechanistic and animal evidence is substantial, but no adequately powered human clinical trials specifically investigating diosgenin for diabetes or metabolic syndrome have been identified in the reviewed literature.
Studies indicate that diosgenin may protect against bone loss in experimental models of senescence, menopause, and retinoic acid-induced osteoporosis. However, the mechanism of action is still not clear but can be associated with a modulation on the receptor activator of NF-κB ligand/osteoprotegerin ratio. Recent animal research has further investigated mechanisms linking diosgenin's phytoestrogen-like actions to bone homeostasis, including via activation of estrogen receptor alpha (ERα)-dependent signaling pathways that affect serotonin levels and sympathetic nervous system activity.
Evidence Strength: Preclinical only. No human clinical trials on bone density or osteoporosis outcomes have been identified.
The present data suggest that diosgenin reduces the production of inflammatory mediators by inhibiting LPS/IFN-γ-triggered CK2, JNK, NF-κB, and AP-1 activation, thereby implicating a mechanism by which diosgenin may exert its immunosuppressive effects. In animal models of acute lung injury, diosgenin inhibited the NF-κB p65/p50 and p38MAPK pathways, mitigating acute lung damage caused by lipopolysaccharide.
The effects of diosgenin in a mouse model of Graves' disease were also investigated, and it was observed that this steroid can relieve goiter through the inhibition of thyrocyte proliferation. The mechanisms for this action involve the suppression of IGF-1, NF-κB, cyclin D1, and PCNA expression.
Evidence Strength: Preclinical (in vitro and animal). Human evidence is absent for these specific indications.
In a study on renal tubular fibrosis, diosgenin, because of its anti-inflammatory effects, also played a protective role against high glucose-induced renal tubular fibrosis possibly by means of the epithelial-to-mesenchymal transition (EMT) pathway. The effectiveness of diosgenin as an antioxidant agent was also evident from its effect on the renal antioxidant system and oxidative markers such as myeloperoxidase and lipid peroxidation. Conversely, based on a single study in rats, oral Dioscorea villosa should be avoided in people with compromised renal function.
Evidence Strength: Exclusively preclinical and contradictory; some animal models suggest protective effects, while at least one rat study signals potential renal risk in the context of compromised kidney function.
There are no established human recommended daily intakes or approved therapeutic dosages for diosgenin as an isolated compound. The following dosages are drawn directly from specific studies as reported in the primary literature:
There are inadequate clinical trials on which to base dosing guidelines for diosgenin or wild yam preparations in humans.
The main therapeutic limitations of diosgenin are represented by its low bioavailability; therefore, a special emphasis is being paid to the production of nanoformulations or conjugate complexes to improve the compound's bioavailability and pharmacokinetic features to develop it into a possible medicine. The bioavailability of diosgenin in the presence of β-cyclodextrin derivatives was near 4- to 11-fold higher than that of a diosgenin suspension, illustrating the substantial impact of formulation on absorption. The potential of this chemical, its analogs, or combinations of this molecule with others has been demonstrated; however, carrier systems such as nanoparticles must be developed to govern diosgenin to the site of action, boosting effectiveness and lowering adverse impacts. For example, encapsulated diosgenin PCL-pluronic nanoparticles (PCL-F68-D-NPs) were developed by the nanoprecipitation method to improve performance in brain cancer therapy.
Diosgenin, leveraging its unique chemical structure, pharmacological properties, and in vivo metabolic characteristics, holds potential for improving bioavailability through the adaptability of its absorption and metabolic mechanisms, such as the enterohepatic circulation.
Only a few articles have acknowledged diosgenin's toxicity, even though there has been substantial research on its role in the treatment and prevention of cancer and other chronic disorders. Clinical investigations have demonstrated diosgenin's nontoxic nature and promising benefits on cognitive function and menopause. However, further well-designed clinical trials are needed to address the other effects seen in preclinical studies, as well as a better knowledge of the diosgenin's safety profile.
Topical preparations of wild yam extract are relatively free from adverse effects. Topical D. villosa (with an upper limit of 3.5% diosgenin) was not found to be systemically toxic or genotoxic. A clinical study evaluating the daily consumption of wild yam reported no adverse events.
Based on a single study in rats, oral D. villosa should be avoided in people with compromised renal function. This precautionary finding has not yet been replicated or evaluated in human populations with renal insufficiency.
In in vitro and in vivo models, diosgenin was demonstrated to exert antithrombotic activity via inhibition of platelet aggregation and thrombosis and by prolonging APTT, PT, and TT in rats in a dose-dependent manner. This finding raises theoretical concerns about combined use with anticoagulant or antiplatelet drugs, though human pharmacokinetic and interaction data are absent.
Diosgenin, a phytosteroid saponin, is used in many traditional medicines, nutraceuticals, dietary supplements, and hormone replacement therapies. It is important to be aware of the potential risks associated with diosgenin, as well as its potential to cause reproductive and endocrine toxicity. Due to the lack of research on safety and probable adverse side effects, one group evaluated the endocrine-disrupting and reproductive toxicity of diosgenin in albino mice following acute toxicity (OECD-423), repeated dose 90-day oral toxicity (OECD-468), and F1 extended one-generation reproductive toxicity (OECD-443) studies. Diosgenin triggered transgenerational reproductive toxic effects in the offspring. These findings are from animal models and their relevance to humans has not been established, but they underscore the need for caution regarding use in pregnancy and in reproductive-age populations until human data are available.
Information regarding safety and efficacy in pregnancy and lactation is lacking. The animal reproductive toxicity data described above reinforce a precautionary position regarding use in these groups.
In vivo experiments revealed a limited inhibitory impact on cytochrome P450 enzymes (CYPs), suggesting that diosgenin fused with any other medicine would be relatively safe from that standpoint. However, this inference is based on limited preclinical data, and formal drug–drug interaction studies in humans have not been published.
Diosgenin may enhance estradiol binding to estrogen receptors and may stimulate growth of mammary tissue. This potential estrogenic activity, while weak and incompletely characterized in humans, is relevant to individuals with hormone-sensitive conditions.
Health conditions that Diosgenin may help support.
Body systems that Diosgenin may help support.
Go back